CD8A and type 2 diabetes mellitus: Metformin, a prescribed drug for type 2 diabetes, has been reported to protect CD8+ tumor-infiltrating lymphocytes from apoptosis and exhaustion characterized by decreased production of IL-2, TNF-α, and interferon-γ (IFN-γ) via AMP-activated protein kinase (AMPK) activation.